DSG2 and Miyoshi myopathy: Importantly though, each of the other six subgroups also harboured a subset of DSG2‐high samples, ranging from 6.9% to 36.2% of the patients (Fig. 3C), and DSG2 retained overall prognostic significance after adjusting for all MM genetic subgroups concurrently (HR 3.03, 95% CI 1.75–5.25, P < 0.001; Model 2 in Table S1).